NCT03321981 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03321981
Title	MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer
Recruitment	Completed
Gender	female
Phase	Phase II
Variant Requirements	No
Sponsors	Merus N.V.
Indications	Her2-receptor positive breast cancer estrogen-receptor positive breast cancer
Therapies	Letrozole + Zenocutuzumab Anastrozole + Zenocutuzumab Fulvestrant + Zenocutuzumab Exemestane + Zenocutuzumab Trastuzumab + Zenocutuzumab Trastuzumab + Vinorelbine + Zenocutuzumab
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| GBR \| FRA \| ESP \| BEL

NCT03321981
Clinical Trial Detail